Robust T cell activation requires an eIF3-driven burst in T cell receptor translation

Author:

De Silva Dasmanthie12ORCID,Ferguson Lucas1,Chin Grant H1,Smith Benjamin E3,Apathy Ryan A4,Roth Theodore L4,Blaeschke Franziska5,Kudla Marek1,Marson Alexander45678,Ingolia Nicholas T19ORCID,Cate Jamie HD1210911ORCID

Affiliation:

1. Department of Molecular and Cell Biology, University of California-Berkeley

2. The J. David Gladstone Institutes

3. School of Optometry, University of California, Berkeley

4. Department of Microbiology and Immunology, University of California, San Francisco

5. Gladstone-UCSF Institute of Genomic Immunology

6. Diabetes Center, University of California, San Francisco

7. Chan Zuckerberg Biohub

8. Department of Medicine, University of California, San Francisco

9. California Institute for Quantitative Biosciences, University of California, Berkeley

10. Innovative Genomics Institute, University of California, Berkeley

11. Department of Chemistry, University of California-Berkeley

Abstract

Activation of T cells requires a rapid surge in cellular protein synthesis. However, the role of translation initiation in the early induction of specific genes remains unclear. Here, we show human translation initiation factor eIF3 interacts with select immune system related mRNAs including those encoding the T cell receptor (TCR) subunits TCRA and TCRB. Binding of eIF3 to the TCRA and TCRB mRNA 3’-untranslated regions (3’-UTRs) depends on CD28 coreceptor signaling and regulates a burst in TCR translation required for robust T cell activation. Use of the TCRA or TCRB 3’-UTRs to control expression of an anti-CD19 chimeric antigen receptor (CAR) improves the ability of CAR-T cells to kill tumor cells in vitro. These results identify a new mechanism of eIF3-mediated translation control that can aid T cell engineering for immunotherapy applications.

Funder

National Institutes of Health

Tang Prize for Biopharmaceutical Science

Damon Runyon Cancer Research Foundation

Care-for-Rare Foundation

German Research Foundation

Burroughs Wellcome Fund

Cancer Research Institute

Chan Zuckerberg Initiative

Innovative Genomics Institute

Parker Institute for Cancer Immunotherapy

Publisher

eLife Sciences Publications, Ltd

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3